Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin

Abstract Introduction The blood coagulation cascade consists of two pathways, the tissue factor (TF)-dependent extrinsic pathway and the contact factor-dependent intrinsic pathway. We have previously shown that a direct thrombin inhibitor, melagatran, paradoxically increased TF-induced thrombin gene...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thrombosis research 2015-09, Vol.136 (3), p.658-662
Hauptverfasser: Furugohri, Taketoshi, Morishima, Yoshiyuki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 662
container_issue 3
container_start_page 658
container_title Thrombosis research
container_volume 136
creator Furugohri, Taketoshi
Morishima, Yoshiyuki
description Abstract Introduction The blood coagulation cascade consists of two pathways, the tissue factor (TF)-dependent extrinsic pathway and the contact factor-dependent intrinsic pathway. We have previously shown that a direct thrombin inhibitor, melagatran, paradoxically increased TF-induced thrombin generation (TG) in thrombomodulin (TM)-containing human plasma in vitro. However, the effect of melagatran on the intrinsic pathway-induced TG remains to be investigated. We investigated whether melagatran enhances the intrinsic pathway-induced TG. Methods and results TG was induced by kaolin in human plasma and assayed by the calibrated automated thrombography method. Melagatran at 150 and 300 nM significantly increased the peak level (2.40-fold) and endogenous thrombin potential of TG in normal plasma in the presence of 5 nM TM. In the absence of TM or in protein C (PC)-deficient plasma, the paradoxical enhancement of TG by melagatran disappeared. A direct FXa inhibitor, edoxaban, and an antithrombin-dependent anticoagulant, unfractionated heparin (UFH), did not increase, but simply decreased TG under each condition in a concentration dependent manner. Conclusion Melagatran enhanced the intrinsic pathway-induced TG as well as the extrinsic pathway-induced TG in human plasma under the condition where PC system is active. In contrast, edoxaban and UFH showed concentration-dependent decrease of TG, but no enhancement. These results indicated that edoxaban and UFH may have a low risk of the paradoxical enhancement of TG by both the extrinsic and intrinsic pathway activation.
doi_str_mv 10.1016/j.thromres.2015.06.034
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1708162101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0049384815300505</els_id><sourcerecordid>1708162101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-f191ef7c709e70372ba7cc6a6da70f972a278bb62f99400b5059b5ba03f929583</originalsourceid><addsrcrecordid>eNqFkstu1DAUQCMEokPhFyovWTTBdh6ONwhU8ZIqgQRI7Kxr56bxkNiD7RTm-_gxPEzLa8PKknXu89yiOGO0YpR1T7ZVmoJfAsaKU9ZWtKto3dwpNqwXsuSN4HeLDaWNLOu-6U-KBzFuKWWCyfZ-ccI71veSN5vi-zsIMPhv1sBM0E3gDC7oEvEjSRMS61KwLlpDdpCmr7AvrRtWgwP5WV9bR67QYYBkvcs0mdYFHNnNEBcgek8WnOEKUgB3ToAMNqBJv2Otm6y2yYdzotdEnE8Eczeg_8JHMBkhn-BPPn9MuIPc3cPi3ghzxEc372nx8eWLDxevy8u3r95cPL8sTcPrVI5MMhyFEVSioLXgGoQxHXQDCDpKwYGLXuuOj1I2lOqWtlK3Gmg9Si7bvj4tHh_z7oL_smJMarHR4DyDQ79GxQTtWcezn4x2R9QEH2PAUe2CXSDsFaPqIFBt1a1AdRCoaKeywBx4dlNj1QsOv8JujWXg2RHAPOm1xaCisZitHXelBm__X-PpPynMbN3hAj7jHuPWr8HlPSqmIldUvT-c0eGKWFtTmrdS_wC5islD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1708162101</pqid></control><display><type>article</type><title>Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Furugohri, Taketoshi ; Morishima, Yoshiyuki</creator><creatorcontrib>Furugohri, Taketoshi ; Morishima, Yoshiyuki</creatorcontrib><description>Abstract Introduction The blood coagulation cascade consists of two pathways, the tissue factor (TF)-dependent extrinsic pathway and the contact factor-dependent intrinsic pathway. We have previously shown that a direct thrombin inhibitor, melagatran, paradoxically increased TF-induced thrombin generation (TG) in thrombomodulin (TM)-containing human plasma in vitro. However, the effect of melagatran on the intrinsic pathway-induced TG remains to be investigated. We investigated whether melagatran enhances the intrinsic pathway-induced TG. Methods and results TG was induced by kaolin in human plasma and assayed by the calibrated automated thrombography method. Melagatran at 150 and 300 nM significantly increased the peak level (2.40-fold) and endogenous thrombin potential of TG in normal plasma in the presence of 5 nM TM. In the absence of TM or in protein C (PC)-deficient plasma, the paradoxical enhancement of TG by melagatran disappeared. A direct FXa inhibitor, edoxaban, and an antithrombin-dependent anticoagulant, unfractionated heparin (UFH), did not increase, but simply decreased TG under each condition in a concentration dependent manner. Conclusion Melagatran enhanced the intrinsic pathway-induced TG as well as the extrinsic pathway-induced TG in human plasma under the condition where PC system is active. In contrast, edoxaban and UFH showed concentration-dependent decrease of TG, but no enhancement. These results indicated that edoxaban and UFH may have a low risk of the paradoxical enhancement of TG by both the extrinsic and intrinsic pathway activation.</description><identifier>ISSN: 0049-3848</identifier><identifier>EISSN: 1879-2472</identifier><identifier>DOI: 10.1016/j.thromres.2015.06.034</identifier><identifier>PMID: 26188924</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject><![CDATA[Activated protein C ; Anticoagulants - administration & dosage ; Antithrombins - administration & dosage ; Azetidines - administration & dosage ; Benzylamines - administration & dosage ; Blood Coagulation - drug effects ; Blood Coagulation - physiology ; Direct factor Xa inhibitor ; Direct thrombin inhibitor ; Dose-Response Relationship, Drug ; Drug Synergism ; Edoxaban ; Factor Xa Inhibitors - administration & dosage ; Hematology, Oncology and Palliative Medicine ; Heparin - administration & dosage ; Humans ; Intrinsic pathway ; Melagatran ; Pyridines - administration & dosage ; Thiazoles - administration & dosage ; Thrombin - biosynthesis ; Thromboplastin - metabolism]]></subject><ispartof>Thrombosis research, 2015-09, Vol.136 (3), p.658-662</ispartof><rights>Elsevier Ltd</rights><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-f191ef7c709e70372ba7cc6a6da70f972a278bb62f99400b5059b5ba03f929583</citedby><cites>FETCH-LOGICAL-c423t-f191ef7c709e70372ba7cc6a6da70f972a278bb62f99400b5059b5ba03f929583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.thromres.2015.06.034$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26188924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Furugohri, Taketoshi</creatorcontrib><creatorcontrib>Morishima, Yoshiyuki</creatorcontrib><title>Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin</title><title>Thrombosis research</title><addtitle>Thromb Res</addtitle><description>Abstract Introduction The blood coagulation cascade consists of two pathways, the tissue factor (TF)-dependent extrinsic pathway and the contact factor-dependent intrinsic pathway. We have previously shown that a direct thrombin inhibitor, melagatran, paradoxically increased TF-induced thrombin generation (TG) in thrombomodulin (TM)-containing human plasma in vitro. However, the effect of melagatran on the intrinsic pathway-induced TG remains to be investigated. We investigated whether melagatran enhances the intrinsic pathway-induced TG. Methods and results TG was induced by kaolin in human plasma and assayed by the calibrated automated thrombography method. Melagatran at 150 and 300 nM significantly increased the peak level (2.40-fold) and endogenous thrombin potential of TG in normal plasma in the presence of 5 nM TM. In the absence of TM or in protein C (PC)-deficient plasma, the paradoxical enhancement of TG by melagatran disappeared. A direct FXa inhibitor, edoxaban, and an antithrombin-dependent anticoagulant, unfractionated heparin (UFH), did not increase, but simply decreased TG under each condition in a concentration dependent manner. Conclusion Melagatran enhanced the intrinsic pathway-induced TG as well as the extrinsic pathway-induced TG in human plasma under the condition where PC system is active. In contrast, edoxaban and UFH showed concentration-dependent decrease of TG, but no enhancement. These results indicated that edoxaban and UFH may have a low risk of the paradoxical enhancement of TG by both the extrinsic and intrinsic pathway activation.</description><subject>Activated protein C</subject><subject>Anticoagulants - administration &amp; dosage</subject><subject>Antithrombins - administration &amp; dosage</subject><subject>Azetidines - administration &amp; dosage</subject><subject>Benzylamines - administration &amp; dosage</subject><subject>Blood Coagulation - drug effects</subject><subject>Blood Coagulation - physiology</subject><subject>Direct factor Xa inhibitor</subject><subject>Direct thrombin inhibitor</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Synergism</subject><subject>Edoxaban</subject><subject>Factor Xa Inhibitors - administration &amp; dosage</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Heparin - administration &amp; dosage</subject><subject>Humans</subject><subject>Intrinsic pathway</subject><subject>Melagatran</subject><subject>Pyridines - administration &amp; dosage</subject><subject>Thiazoles - administration &amp; dosage</subject><subject>Thrombin - biosynthesis</subject><subject>Thromboplastin - metabolism</subject><issn>0049-3848</issn><issn>1879-2472</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkstu1DAUQCMEokPhFyovWTTBdh6ONwhU8ZIqgQRI7Kxr56bxkNiD7RTm-_gxPEzLa8PKknXu89yiOGO0YpR1T7ZVmoJfAsaKU9ZWtKto3dwpNqwXsuSN4HeLDaWNLOu-6U-KBzFuKWWCyfZ-ccI71veSN5vi-zsIMPhv1sBM0E3gDC7oEvEjSRMS61KwLlpDdpCmr7AvrRtWgwP5WV9bR67QYYBkvcs0mdYFHNnNEBcgek8WnOEKUgB3ToAMNqBJv2Otm6y2yYdzotdEnE8Eczeg_8JHMBkhn-BPPn9MuIPc3cPi3ghzxEc372nx8eWLDxevy8u3r95cPL8sTcPrVI5MMhyFEVSioLXgGoQxHXQDCDpKwYGLXuuOj1I2lOqWtlK3Gmg9Si7bvj4tHh_z7oL_smJMarHR4DyDQ79GxQTtWcezn4x2R9QEH2PAUe2CXSDsFaPqIFBt1a1AdRCoaKeywBx4dlNj1QsOv8JujWXg2RHAPOm1xaCisZitHXelBm__X-PpPynMbN3hAj7jHuPWr8HlPSqmIldUvT-c0eGKWFtTmrdS_wC5islD</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Furugohri, Taketoshi</creator><creator>Morishima, Yoshiyuki</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150901</creationdate><title>Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin</title><author>Furugohri, Taketoshi ; Morishima, Yoshiyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-f191ef7c709e70372ba7cc6a6da70f972a278bb62f99400b5059b5ba03f929583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Activated protein C</topic><topic>Anticoagulants - administration &amp; dosage</topic><topic>Antithrombins - administration &amp; dosage</topic><topic>Azetidines - administration &amp; dosage</topic><topic>Benzylamines - administration &amp; dosage</topic><topic>Blood Coagulation - drug effects</topic><topic>Blood Coagulation - physiology</topic><topic>Direct factor Xa inhibitor</topic><topic>Direct thrombin inhibitor</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Synergism</topic><topic>Edoxaban</topic><topic>Factor Xa Inhibitors - administration &amp; dosage</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Heparin - administration &amp; dosage</topic><topic>Humans</topic><topic>Intrinsic pathway</topic><topic>Melagatran</topic><topic>Pyridines - administration &amp; dosage</topic><topic>Thiazoles - administration &amp; dosage</topic><topic>Thrombin - biosynthesis</topic><topic>Thromboplastin - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furugohri, Taketoshi</creatorcontrib><creatorcontrib>Morishima, Yoshiyuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furugohri, Taketoshi</au><au>Morishima, Yoshiyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin</atitle><jtitle>Thrombosis research</jtitle><addtitle>Thromb Res</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>136</volume><issue>3</issue><spage>658</spage><epage>662</epage><pages>658-662</pages><issn>0049-3848</issn><eissn>1879-2472</eissn><abstract>Abstract Introduction The blood coagulation cascade consists of two pathways, the tissue factor (TF)-dependent extrinsic pathway and the contact factor-dependent intrinsic pathway. We have previously shown that a direct thrombin inhibitor, melagatran, paradoxically increased TF-induced thrombin generation (TG) in thrombomodulin (TM)-containing human plasma in vitro. However, the effect of melagatran on the intrinsic pathway-induced TG remains to be investigated. We investigated whether melagatran enhances the intrinsic pathway-induced TG. Methods and results TG was induced by kaolin in human plasma and assayed by the calibrated automated thrombography method. Melagatran at 150 and 300 nM significantly increased the peak level (2.40-fold) and endogenous thrombin potential of TG in normal plasma in the presence of 5 nM TM. In the absence of TM or in protein C (PC)-deficient plasma, the paradoxical enhancement of TG by melagatran disappeared. A direct FXa inhibitor, edoxaban, and an antithrombin-dependent anticoagulant, unfractionated heparin (UFH), did not increase, but simply decreased TG under each condition in a concentration dependent manner. Conclusion Melagatran enhanced the intrinsic pathway-induced TG as well as the extrinsic pathway-induced TG in human plasma under the condition where PC system is active. In contrast, edoxaban and UFH showed concentration-dependent decrease of TG, but no enhancement. These results indicated that edoxaban and UFH may have a low risk of the paradoxical enhancement of TG by both the extrinsic and intrinsic pathway activation.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>26188924</pmid><doi>10.1016/j.thromres.2015.06.034</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0049-3848
ispartof Thrombosis research, 2015-09, Vol.136 (3), p.658-662
issn 0049-3848
1879-2472
language eng
recordid cdi_proquest_miscellaneous_1708162101
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Activated protein C
Anticoagulants - administration & dosage
Antithrombins - administration & dosage
Azetidines - administration & dosage
Benzylamines - administration & dosage
Blood Coagulation - drug effects
Blood Coagulation - physiology
Direct factor Xa inhibitor
Direct thrombin inhibitor
Dose-Response Relationship, Drug
Drug Synergism
Edoxaban
Factor Xa Inhibitors - administration & dosage
Hematology, Oncology and Palliative Medicine
Heparin - administration & dosage
Humans
Intrinsic pathway
Melagatran
Pyridines - administration & dosage
Thiazoles - administration & dosage
Thrombin - biosynthesis
Thromboplastin - metabolism
title Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T13%3A53%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Paradoxical%20enhancement%20of%20the%20intrinsic%20pathway-induced%20thrombin%20generation%20in%20human%20plasma%20by%20melagatran,%20a%20direct%20thrombin%20inhibitor,%20but%20not%20edoxaban,%20a%20direct%20factor%20Xa%20inhibitor,%20or%20heparin&rft.jtitle=Thrombosis%20research&rft.au=Furugohri,%20Taketoshi&rft.date=2015-09-01&rft.volume=136&rft.issue=3&rft.spage=658&rft.epage=662&rft.pages=658-662&rft.issn=0049-3848&rft.eissn=1879-2472&rft_id=info:doi/10.1016/j.thromres.2015.06.034&rft_dat=%3Cproquest_cross%3E1708162101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1708162101&rft_id=info:pmid/26188924&rft_els_id=S0049384815300505&rfr_iscdi=true